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ABSTRACT
Background Patients with schizophrenia are a high- risk 
population due to higher prevalences of cardiovascular 
risk factors and comorbidities that contribute to shorter life 
expectancy.
Purpose To investigate patients with and without 
schizophrenia experiencing an acute myocardial infarction 
(AMI) in relation to guideline recommended in- hospital 
management, discharge medications and 5- year major 
adverse cardiac events (MACE: composite of all- cause 
mortality, rehospitalisation for reinfarction, stroke or heart 
failure).
Methods All patients with schizophrenia who experienced 
AMI during 2000–2018 were identified (n=1008) from 
the nationwide Swedish Web- system for Enhancement 
and Development of Evidence- based care in Heart 
disease Evaluated According to Recommended Therapies 
registry and compared with AMI patients without 
schizophrenia (n=2 85 325). Kaplan- Meier survival curves 
and multivariable Cox regression models were used to 
compare the populations.
Results Patients with schizophrenia presented with 
AMI approximately 10 years earlier (median age 64 vs 
73 years), and had higher prevalences of diabetes, heart 
failure and chronic obstructive pulmonary disease. They 
were less likely to be invasively investigated or discharged 
with aspirin, P2Y12 inhibitors, ACE inhibitors/angiotensin II 
receptor blockers, beta- blockers and statins (all p<0.005). 
AMI patients with schizophrenia had higher adjusted 
risk of MACE (aHR=2.05, 95% CI 1.63 to 2.58), mortality 
(aHR=2.38, 95% CI 1.84 to 3.09) and hospitalisation for 
heart failure (aHR=1.39, 95% CI 1.04 to 1.86) compared 
with AMI patients without schizophrenia.
Conclusion Patients with schizophrenia experienced 
an AMI almost 10 years earlier than patients without 
schizophrenia. They less often underwent invasive 
procedures and were less likely to be treated with 
guideline recommended medications at discharge, 
and had more than doubled risk of MACE and all- 
cause mortality. Improved primary and secondary 
preventive measures, including adherence to guideline 
recommendations, are warranted and may improve 
outcome.
INTRODUCTION
Patients with schizophrenia constitute a 
high- risk population partially attributed 
to increased prevalence of cardiovascular 
risk factors such as diabetes, hypertension, 
metabolic syndrome, smoking as well as 
unhealthy eating habits and low physical 
activity compared with the general popula-
tion.1–3 Cardiovascular disease is the leading 
cause of death in patients with schizo-
phrenia, accounting for far more deaths 
than suicide.4 Schizophrenia is accompanied 
by a twofold to threefold increased risk of 
the two most frequent cardiovascular death 
causes, coronary heart disease (CHD) and 
cerebrovascular disease, compared with the 
general population and half of the deaths 
from CHD are caused by acute myocardial 
infarctions (AMI).5 6 Notably, several studies 
Key questions
What is already known about this subject?
 ► Patients with schizophrenia are a high- risk popu-
lation with increased mortality, mainly attributed to 
cardiovascular diseases because of highly prevalent 
modifiable cardiovascular risk factors.
What does this study add?
 ► A nationwide analysis of the major adverse cardiac 
events after acute myocardial infarction (AMI) in a 
population with schizophrenia, using the Swedish 
Web- system for Enhancement and Development 
of Evidence- based care in Heart disease 
Evaluated According to Recommended Therapies 
(SWEDEHEART) registry. Our study indicates that the 
use of guideline recommended therapy in this pop-
ulation following discharge is lower than in patients 
without schizophrenia, contributing to the worse 
outcome seen in this population.
How might this impact on clinical practice?
 ► Our results highlight the extent of risk patients with 
schizophrenia have after an AMI and that they are 
treated to a lower extent with guideline- based med-
ications. We argue that a multidisciplinary approach 
should be considered to improve risk factor control, 
guideline- based treatment and outcome in this 
high- risk population.
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have concluded that patients with schizophrenia receive 
suboptimal preventive and cardiac care despite being at 
such high risk.7–10 Furthermore, the use of atypical antip-
sychotic medications also contributes to the development 
of metabolic syndrome and consequently increases the 
risk of cardiovascular disease.11
Despite the increased interest in this topic, there is a 
lack of comprehensive studies of the schizophrenia popu-
lation with regards to comorbidities, in- hospital treat-
ment, discharge medications and outcomes following 
AMI in contemporary nationwide study samples. The 
aim of this study was therefore to describe characteris-
tics of, and the use of guideline recommended secondary 
preventive medications at discharge and 5- year risk of 
major adverse cardiac events (MACE: all- cause mortality, 
rehospitalisation for AMI, hospitalisation for stroke or 
heart failure) in patients with and without schizophrenia 
experiencing an AMI.
METHODS
Study sample
This nationwide observational follow- up study included 
all patients aged ≥18 years with a ST- segment eleva-
tion MI (STEMI) or non- STEMI (NSTEMI) diagnosis 
between 1 January 2000 and 29 May 2018 and registered 
in the Swedish Web- system for Enhancement and Devel-
opment of Evidence- based care in Heart disease Evalu-
ated According to Recommended Therapies (SWEDE-
HEART) registry. The patient cohort was divided into 
patients with and without a schizophrenia diagnosis. 
The STEMI and NSTEMI diagnoses were determined 
clinically, and only those with a final discharge diag-
nosis (I21.0–I21.4), defined by the WHO’s 10th version 
of International Classification of Disease (ICD-10) diag-
nosis codes, were included in the study. Schizophrenia 
was defined as having an ICD-9 code of 295 (used in 
1987–1996) or an ICD-10 diagnosis code (used from 1997 
and onwards) of schizophrenia (F20) or schizoaffective 
disorder (F25) at an outpatient visit or in- hospital admis-
sion before the index AMI event.
National registries
SWEDEHEART contains information on risk factors, 
medical history, cardiac procedures, treatments during 
hospitalisation and discharge medications. Using the 
unique personal identification number given to each 
citizen in Sweden, the SWEDEHEART registry was linked 
to the National Population Register and National Patient 
Registry to obtain further information such as date of 
death, schizophrenia diagnoses and other non- cardiac 
comorbidities.12 All personal identification numbers 
were replaced with an unique SWEDEHEART number to 
ensure anonymity.
Outcomes
The primary outcome was a 5- year composite MACE 
comprised all- cause mortality, rehospitalisation for AMI, 
hospitalisation for stroke or heart failure. The secondary 
outcomes were the individual components of MACE 
and bleeding requiring hospitalisation (fatal, cerebral 
or bleeding requiring surgery or transfusion, defined 
by ICD-9 (430, 431, 432, 578, 285B, 456A, 531A, 531C, 
531E, 531G, 532A, 532C, 532E, 532G, 533A, 533C, 533E, 
533G, 534A, 534C, 534E, 534G and 569D) and ICD-10 
(I60, I61, I62, D629, I850, K226, K250, K252, K254, K256, 
K260, K262, K264, K266, K270, K272, K274, K276, K280, 
K282, K284, K286, K290, K625, K920, K921 and K922) 
codes) at 5 years following discharge. Other investigated 
secondary outcomes were proportion treated with guide-
line recommended discharge medications, patient and 
system delays and length of hospital stay during hospi-
talisation for AMI. Length of hospital stay was measured 
from admission time to discharge time. Patient delay was 
measured as the time from symptom onset to ECG meas-
urement, a surrogate for first medical contact and system 
delay was measured from first medical contact to percuta-
neous coronary intervention (PCI).
Statistical analysis
Continuous variables are expressed as means with SD or 
medians with 1st–3rd quartiles and categorical variables 
as counts with percentages. Differences in baseline varia-
bles between the populations were analysed using Mann- 
Whitney U tests and Student’s t- test for continuous vari-
ables and χ2 tests for categorical variables. Time- to- event 
outcomes were analysed and compared using the Kaplan- 
Meier survival estimator and log- rank tests as well as univar-
iable and multivariable Cox proportional hazard models, 
presented as HRs with 95% CIs. The results are presented 
in four different models, the first model represents the 
crude HR, the second model adjusted for age and sex 
and the third model adjusted for age, sex, previous proce-
dures and comorbidities (previous PCI, previous coronary 
artery bypass grafting (CABG), previous AMI, congestive 
heart failure, chronic kidney disease, chronic obstructive 
pulmonary disease (COPD), peripheral artery disease, 
previous bleeding requiring hospitalisation (defined 
as the bleeding outcome described earlier), stroke, 
diabetes, hypertension, hyperlipidaemia and smoking 
status). The fourth model additionally adjusted for revas-
cularisation method during hospitalisation (PCI, CABG 
or medical management) and guideline recommended 
discharge medications (ACE- inhibitors or angiotensin II 
receptor blockers (ARBs), beta- blockers, statins, aspirin 
and P2Y12 inhibitors). Regression analyses in the final 
model only included hospital survivors. For the outcome 
MI, we used a 30- day blanking period as any early read-
missions (follow- up visit or readmission) within 30 days 
from the index event may be incorrectly registered as a 
reinfarction in the database, for example, due to trans-
fers between hospitals or coding practices. To prevent 
bias due to the long inclusion period and improvement 
of treatment over time we performed a sensitivity anal-
ysis including year of MI in the final regression model 
of MACE. Guideline recommended medications were 
additionally analysed using multiple logistic regressions 
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adjusting for baseline characteristics, as described in the 
third model. All p values were two- tailed and a value <0.05 
was considered statistically significant. Statistical analyses 
were performed using STATA V.14.0 and SPSS V.25.
RESULTS
Baseline characteristics
The baseline characteristics of the cohort are outlined 
in table 1. Patients with schizophrenia (n=1008) were 
younger than those without schizophrenia (n=285 325) 
(median 64 vs 73 years) at the time of the AMI, less likely 
to be under employment and more often on sick leave 
(all p value <0.001). Patients with schizophrenia were also 
more often current smokers and fewer had never smoked 
(p value <0.001). They also had a higher prevalence of 
diabetes, heart failure, COPD and previous bleeding 
but a lower prevalence of hypertension, chronic kidney 
disease and peripheral artery disease. Patients with 
schizophrenia also had fewer previous PCI and CABG 
performed despite not having fewer previous myocardial 
infarctions.
Clinical presentation
Clinical presentation during hospitalisation for AMI 
are shown in tables 2 and 3. Patients with schizophrenia 
had higher creatinine, triglyceride and CRP levels, and 
lower cholesterol levels compared with the population 
without schizophrenia. They also had lower systolic blood 
pressure, higher heart rates and more often presented 
with dyspnoea and cardiac arrest, as opposed to chest 
pain which was the most common symptom in the non- 
schizophrenia population. Sinus rhythm as well as left 
and right bundle branch blocks and pathological Q 
waves were more common in the schizophrenia popula-
tion, while their ECG less often showed atrial fibrillation 
or flutter compared with patients without schizophrenia. 
Table 1 Baseline characteristics for all acute myocardial infarction patients with and without schizophrenia between 2000 
and 2018 in Sweden
Schizophrenia
(n=1008)
Without schizophrenia
(n=285 325)
Total
(n=286 333) Missing n (%) P value
Age median (1st–3rd quartiles) 64 (56–71) 73 (63–81) 71.3 (12.3) 0 <0.001
Male sex, n (%) 652 (64.7) 183 568 (64.0) 183 220 (64.0) 0 0.646
Occupational status, n (%) 58 897 (20.6) <0.001
  Working 46 (4.6) 48 611 (17.0) 48 657 (17.0)
  Sick leave 102 (10.1) 4675 (1.6) 4777 (1.7)
  Unemployed 16 (1.6) 2988 (1.1) 2004 (1.1)
  Retired 574 (56.9) 162 199 (56.9) 162 773 (56.9)
  Student/other 12 (1.2) 679 (0.2) 691 (0.2)
Smoking status, n (%) 25 047 (8.8) <0.001
  Never 224 (22.2) 116 923 (41.0) 117 147 (40.9)
  Ex- smoker (>1 month) 184 (18.3) 86 514 (30.3) 86.7 (30.3)
  Smoker 489 (48.5) 56 953 (20.0) 57 441 (20.1)
Diabetes, n (%) 394 (39.1) 68 429 (24.0) 68 823 (24.0) 0 <0.001
Hypertension 454 (45.0) 158 726 (55.6) 159 180 (55.6) 0 <0.001
Hyperlipidaemia 305 (30.3) 93 157 (32.7) 93 462 (32.6) 3786 (1.3) 0.062
Previous myocardial infarction, n (%) 250 (24.8) 76 102 (26.7) 76 352 (26.7) 0 0.18
Previous PCI, n (%) 79 (7.8) 30 523 (10.7) 30 602 (10.1) 0 0.003
Previous CABG, n (%) 29 (2.9) 20 823 (7.3) 20 852 (7.3) 0 <0.001
Previous stroke, n % 126 (12.5) 34 392 (12.1) 34 518 (12.1) 0 0.664
Heart failure, n (%) 200 (19.8) 43 624 (15.3) 43 824 (15.3) 0 <0.001
Chronic kidney disease, n (%) 201 901 (70.5) 0.031
  Stage 1 (GFR>90 mL/min/1.73 m2) 212 (21.0) 67 610 (23.7) 67 822 (23.7)
  Stage 2 (GFR of 60–89 mL/min/1.73 m2) 43 (4.3) 14 859 (5.2) 14 902 (5.2)
  Stage 3 (GFR of 30–59 mL/min/1.73 m2) 10 (1.0) 1698 (0.6) 1708 (0.6)
COPD, n (%) 132 (13.1) 20 008 (7.0) 20 140 (7.0) 0 <0.001
Previous bleeding, n (%) 74 (7.3) 16 765 (5.9) 16 839 (5.9) 0 0.048
Peripheral artery disease, n (%) 42 (4.2) 16 799 (5.9) 16 841 (5.9) 0 0.02
CABG, coronary artery bypass graft; COPD, chronic obstructive pulmonary disease; GFR, glomerular filtration rate; PCI, percutaneous 
coronary intervention.
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Furthermore, a worse left ventricular function was seen 
in the schizophrenia population. During hospitalisation 
fewer patients with schizophrenia received a coronary 
angiography, PCI or CABG.
No statistical differences were seen between the popu-
lations in the patient delay; measured from symptom 
onset to ECG, or system delay; measured from ECG to 
PCI, neither for the STEMI nor NSTEMI group (table 3). 
Patients without schizophrenia were hospitalised for a 
median of 4 days (25th–75th percentiles 4–7) and patients 
with schizophrenia were hospitalised for a median of 5 
days (25th–75th percentiles 4–7), this difference was 
statistically significant (table 3).
Discharge medications
Patients with schizophrenia were less likely to be 
discharged with aspirin, P2Y12 inhibitors, ACE- inhibitors/
ARBs, beta blockers and statins (all p values <0.005; 
table 4). Following multiple logistic regression adjusting 
for age, sex and comorbidities (table 5), schizophrenia 
was independently associated with lower prescription 
rates of ACE- inhibitors/ARBs (OR 0.66, 95% CI 0.47 to 
0.93) and statins (OR 0.3, 95% CI 0.25 to 52).
Outcomes
The clinical outcomes following AMI are shown in 
table 6 and figure 1. Patients with schizophrenia had 
higher occurrence of MACE with an unadjusted HR of 
1.35 (95% CI 1.23 to 1.47). After adjustment for age and 
sex in model 2 the HR increased to 2.44 (95% CI 2.23 to 
2.67). Further adjustments for comorbidities in model 3 
slightly decreased the HR to 2.20 (95% CI 1.79 to 2.71) 
and additional adjustments for revascularisation method 
and discharge medications in the final model 4 resulted 
in a HR of 2.05 (95% CI 1.63 to 2.58). The unadjusted 
HR for mortality in model 1 was 1.44 (95% CI 1.31 to 
1.59), after adjustments the HR in model 2 was 2.99 (95% 
CI 2.72 to 3.29), in model 3: 2.53 (95% CI 1.00 to 3.21) 
and in model 4: 2.38 (95% CI 1.84 to 3.09), respectively. 
The HR for heart failure was increased for patients with 
schizophrenia in all models; the unadjusted HR in model 
1 was 1.25 (95% CI 1.10 to 1.42), model 2 HR 2.14 (95% 
CI 1.88 to 2.42), model 3 HR 1.49 (95% CI 1.13 to 1.98) 
and model 4 HR 1.39 (95% CI 1.04 to 1.86). For reinfarc-
tion, stroke and bleeding a difference between the popu-
lations was only seen in model 2, with HR of 1.53 (95% CI 
1.25 to 1.89) for reinfarction, 1.67 (95% CI 1.29 to 2.17) 
for stroke and 1.55 (95% CI 1.23 to 1.95) for bleeding in 
patients with schizophrenia.
Sensitivity analysis
Additionally adjusting for inclusion year did not alter the 
results in the final model 3 of MACE: HR 2.08 (95% CI 
1.67 to 2.60).
DISCUSSION
The primary findings of this nationwide study were as 
follows. Patients with schizophrenia presented approxi-
mately 10 years earlier with AMI, but had an increased 
absolute risk for MACE (all- cause mortality, reinfarction, 
stroke or heart failure), all- cause death and heart failure, 
within 5 years, compared with patients without schizo-
phrenia. After adjustments for multiple confounders, 
patients with schizophrenia had a more than doubled 
risk of MACE and mortality after AMI, compared with 
patients without schizophrenia.
We found large outcome differences in relation to 
schizophrenia; after adjustments for age and sex, we 
found that patients with schizophrenia had an increased 
risk of the composite endpoint MACE and all individual 
endpoints. After further adjustment for comorbidities and 
treatment the HR remained more than double for MACE 
and mortality and almost one and a half times higher 
for heart failure. In a comparable study conducted in 
Denmark1 investigating MACE following acute coronary 
syndrome in patients with schizophrenia, the researchers 
found an increased risk of MACE and all- cause mortality, 
Table 2 Laboratory findings in the population with and without schizophrenia during hospitalisation for acute myocardial 
infarction
Schizophrenia
(n=1008)
Without schizophrenia
(n=285 325)
Total
(n=286 333) Missing n (%) P value
Creatinine μmol/L mean (SD) 103.4 (87.0) 97.62 (62.0) 97.65 (62.1) 58 710 (20.5) 0.007
Haemoglobin g/L mean (SD) 134.4 (18.8) 136.6 (18.2) 136.60 (18.2) 105 031 (36.7) 0.002
Triglycerides mmol/L mean (SD) 1.85 (1.3) 1.63 (1.2) 1.63 (1.2) 286 333 (39.7) <0.001
Cholesterol mmol/L mean (SD) 4.83 (1.3) 5.00 (1.5) 4.99 (1.5) 102 865 (36.0) 0.005
CRP mg/L mean (SD) 34.86 (60.4) 22.15 (46.4) 22.20 (46.5) 77 192 (27.0) <0.001
Coronary marker levels ng/L mean (SD)
  Troponin T 45.5 (283.2) 52.1 (496.7) 52.1 (496.3) 11 224 (3.9) 0.054
  Troponin I 20.7 (39.4) 24.2 (135.5) 24.2 (135.2)
  CKMB 99.7 (130.8) 111.3 (197.5) 111.3 (197.4)
CKMB, creatine kinase myocardial band; CRP, C reactive protein.
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Table 3 Clinical presentation of acute myocardial infarction in the population with and without schizophrenia
Schizophrenia 
(n=1008) Without 
schizophrenia
(n=285 325)
Total
(n=286 333)
Missing n (%) P value
Systolic blood pressure mm Hg mean (SD) 137.5 (30.9) 146.3 (30.0) 146.2 (30.0) 68 244 (23.8) <0.001
Diastolic blood pressure mm Hg mean (SD) 82.3 (19.1) 83.6 (21.6) 83.6 (21.6) 75 050 (26.2) 0.103
Heart rate bpm mean (SD) 88.5 (23.0) 81.7 (23.4) 81.8 (23.4) 68 234 (23.8) <0.001
Presenting symptoms, n (%) 15 216 (5.3) <0.001
  Chest pain 684 (67.9) 224 910 (78.8) 225 594 (78.8)
  Dyspnoea 109 (10.8) 17 420 (6.1) 17 529 (6.1)
  Cardiac arrest 20 (2.0) 3638 (1.3) 3658 (1.3)
  Other 195 (19.3) 39 357 (13.8) 39 552 (13.8)
Infarct type, n (%) 3734 (1.3) 0.665
  STEMI 343 (34.0) 95 833 (33.6) 96 176 (33.6)
  NSTEMI 655 (65.0) 185 768 (65.1) 186 423 (65.1)
ECG: rhythm, n (%) 3737 (1.3) <0.001
  Sinus 896 (88.9) 238 996 (83.8) 239 892 (83.8)
  Atrial fibrillation/flutter 72 (7.1) 32 865 (11.5) 32 937 (11.5)
  Other 40 (4.0) 13 464 (4.7) 13 504 (4.72)
ECG: QRS, n (%) 46 187 (16.1) <0.001
  Normal 534 (53.0) 169 196 (59.3) 169 730 (59.3)
  Pacemaker 10 (1.0) 4002 (1.4) 2013 (1.4)
  LBBB 68 (6.8) 18 783 (6.6) 18 851 (6.6)
  RBBB 47 (4.7) 10 391 (3.6) 10 438 (3.7)
  Pathological Q- wave 185 (18.4) 36 920 (13.0) 37 115 (13.0)
  Other 163 (16.27) 46 023 (16.1) 46 187 (16.1)
Left ventricular function, n (%) 104 452 (36.5) <0.001
  Normal ≥50% 257 (25.5) 98 864 (34.7) 99 121 (34.6)
  Slightly decreased 40%–49% 160 (15.9) 42 118 (14.8) 42 278 (14.8)
  Moderately decreased 30%–39% 127 (12.6) 26 530 (9.3) 26 657 (9.3)
  Severely decreased <30% 97 (9.6) 13 728 (4.8) 13 825 (4.8)
CAG, n (%) 573 (58.9) 180 790 (63.4) 181 363 (63.4) 0 <0.001
PCI, n (%) 447 (44.5) 141 471 (49.6) 141 918 (49.6) 0 <0.001
CABG, n (%) 24 (2.4) 10 206 (3.6) 10 230 (3.6) 0 0.041
Angiographic findings, n (%) 0
  Non- conclusive 509 (50.5) 132 599 (46.5) 133 108 (46.5)
  Normal/atheromatosis 36 (3.6) 12 330 (4.3) 12 366 (4.3)
  1- vessel, non- LM 212 (21.0) 62 125 (21.8) 62 337 (21.8)
  2- vessel, non- LM 117 (11.6) 37 811 (13.3) 37 928 (13.3)
  3- vessel, non- LM 103 (10.2) 29 333 (10.3) 29 436 (10.3)
  LMD 31 (3.1) 11 127 (3.9) 11 158 (3.9) 0.273
Length of hospital stay, median days (25th–75th  
percentiles)
5 (3–7) 4 (3–7) 4 (3–7) 0 0.008
Patient delay*, median days (25th–75th  
percentiles)
3.6 (1.5–8.0) 3.3 (1.5–7.0) 3.3 (1.5–7.0) 200 319 (70.0) 0.131
System delay†, median days (25th–75th  
percentiles)
0 0.988
  STEMI 3.1 (2.1–5.3) 3.1 (2.1–4.8) 3.1 (2.1–4.8)
  NSTEMI 25.5 (6.1–48.9) 25.9 (7.9–47.0) 25.9 (7.9–47.0)
Continued
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and additionally an increased risk of stroke. Nonetheless, 
MACE was comprised fewer variables and the adjustment 
models were different in the Danish study. In a system-
atic review13 of mortality in 37 studies found the standard 
mortality rate in schizophrenia to be 2.58, which corre-
sponds with the increased risk found in our study. A large 
scale meta- analysis by Correll et al6 investigating cardio-
vascular disease in patients with severe mental illness like-
wise corroborates the association between increased risk 
of heart failure and schizophrenia seen in our study.
As previously discussed, the increased risks can be 
attributed to multiple mechanisms, among these an 
increased prevalence of various comorbidities in the popu-
lation with schizophrenia. Interestingly, in our study we 
only found increases in baseline prevalences of smoking, 
diabetes, heart failure, COPD and previous bleeding and 
a lower prevalence of hypertension. Furthermore, patients 
with schizophrenia more frequently demonstrated sinus 
rhythm and pathological Q waves on ECGs, which is in line 
with previous work.14 15 The latter may not only be indica-
tive of prior recognised MI but also of unrecognised MI or 
missed STEMI, which is further supported by the fact that 
patients with schizophrenia in our study more frequently 
presented with atypical AMI symptoms (ie, dyspnoea) rather 
than typical (ie, chest pain).
Results regarding comorbidities in AMI patients with 
schizophrenia varies as some studies show an increased 
prevalence of hypertension and hyperlipidaemia,16 17 and 
other studies show lower prevalences of hypertension and 
hyperlipidaemia.1 18 The variation may perhaps be attributed 
to dissimilarity in population size and inclusion criteria or 
under- diagnosis of somatic comorbidities.19 An alternative 
reason can be the lower awareness of comorbidities found 
in patients with schizophrenia20 which may impede care and 
consequently contribute to the increased MACE presented 
in this study. Yet another factor which could contribute is 
physician bias in deprioritising patients with schizophrenia 
during a myocardial infarction. However, in this study we 
found a homogeneity in system and patient delay between 
the populations and a longer LOS in patients with schizo-
phrenia following myocardial infarction, ruling out these 
variables as contributing factors to the increased MACE. 
Finally, we found patients with schizophrenia to more often 
present with cardiac arrest, worse ventricular function during 
hospitalisation and they less often underwent coronary angi-
ography, PCI and CABG during hospitalisation. Adjustment 
for these variables only slightly attenuated the association 
between schizophrenia and poor outcome, indicating that 
other factors remain highly influential.
Following the AMI, there were additional dissimilarities 
as patients with schizophrenia were less likely to receive 
any of the recommended guideline medications during 
discharge: aspirin, P2Y12 inhibitors, ACE- inhibitors/ARBs, 
beta blockers and statins. This was further confirmed after 
adjusted multiple logistic analysis which showed ACE- 
inhibitors/ARBs and statins to be prescribed less frequently. 
These results are in accordance with a study by Mitchell 
et al21 investigating prescription of medication in severe 
mental illness, where they presented evidence for lower 
than expected rates of prescription of ACE- inhibitors/ARBs, 
beta blockers and statins for patients with schizophrenia. A 
Danish study by Kugathasan et al22 investigating the associ-
ation between secondary preventive treatment after AMI 
and mortality found scarcer redeemed prescription of 
guideline recommended medications in a population with 
schizophrenia, and concluded cardioprotective treatment 
following AMI to be fundamental in decreasing cardiovas-
cular mortality in this group, underlining the importance of 
ensuring patients receive guideline recommended medica-
tions following AMI.
Clinical implication
This study found an increase of MACE at 5 years and 
evidence of fewer guideline recommended prescriptions 
*Patient delay was measured as the time from symptom onset to ECG measurement.
†System delay was measured from ECG measurement to PCI.
CABG, coronary artery bypass graft; CAG, coronary angiography; CRP, C reactive protein; LBBB, left bundle branch block; LM, left 
main; LMD, left main disease; NSTEMI, non- ST elevated; PCI, percutaneous coronary intervention; RBBB, right bundle branch block 
; STEMI, ST- elevated myocardial infarction.
Table 3 Continued
Table 4 Recommended medications at discharge following acute myocardial infarction comparing patients with and without 
schizophrenia
Schizophrenia
(n=1008)
Without schizophrenia
(n=285 325)
Total
(n=286 333) Missing n (%) P value
Aspirin, n (%) 844 (83.7) 244 195 (85.6) 245 039 (85.6) 6514 (2.3) 0.001
P2Y12 inhibitor, n (%) 608 (60.3) 178 564 (62.6) 179 172 (62.6) 7848 (2.7) 0.005
ACEi/ARBs, n (%) 249 (24.7) 88 864 (31.1) 89 113 (31.1) 4495 (1.6) <0.001
Beta blockers, n (%) 778 (77.2) 236 069 (82.7) 236 847 (82.7) 6633 (2.3) <0.001
Statins, n (%) 703 (69.7) 210 379 (73.7) 211 082 (73.7) 7096 (2.5) <0.001
ACEi, ACE- inhibitor; ARBs, angiotensin two receptor blocker.
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Coronary artery disease
following AMI. The mechanisms to why these patients 
experience worse outcome are many, but some may be 
modifiable. Improved guideline recommended treatment 
is essential and should not be overlooked in patients with 
schizophrenia. More importantly, primary preventive strate-
gies should be introduced in early stages of these patients’ 
lives and the authors of this study suggest a multidisciplinary 
approach with improved collaboration between psychia-
trists, cardiologists and other involved disciplines in order 
to combat the poor outcome seen in this high- risk patient 
population.
Limitations
First, we included patients over a period of 18 years, in which 
both the treatment options and guideline recommendations 
have changed. We accounted for the possibility of time bias 
by adjusting for year of AMI in a sensitivity analysis, which did 
not alter the results. Second, the patients with schizophrenia 
in our study were almost 10 years younger; whether this is 
attributable to patient selection, that is, older patients with 
schizophrenia are perhaps more conservatively managed 
and not treated in coronary care units or catheterisation labs, 
thus causing an under- representation in the SWEDEHEART 
registry, or a reflection of a greatly accelerated atheroscle-
rotic cardiovascular disease process will have to be furtherly 
investigated in future studies. Finally, this was a register- based 
observational study with known inherent limitations such as 
risk of selection bias and confounding by indication, making 
causal conclusions uncertain, as well as potential underdi-
agnosis and misclassification of ICD- codes resulting in an 
Table 5 ORs of the recommended medications at 
discharge following acute myocardial infarction for patients 
with schizophrenia
OR* 95% CI P value
Aspirin, n (%) 0.67 0.41 to 1.10 0.11
P2Y12 inhibitor, n (%) 0.74 0.54 to 1.01 0.06
ACEi/ARBs, n (%) 0.66 0.47 to 0.93 0.02
Beta blockers, n (%) 0.76 0.53 to 1.10 0.14
Statins, n (%) 0.36 0.25 to 0.52 <0.001
*Adjusted for age, sex, smoking, comorbidities, previous 
coronary angiography and previous percutaneous coronary 
intervention.
ACEi, ACE- inhibitor; ARBs, angiotensin two receptor blocker.
Table 6 Clinical outcomes for patients with schizophrenia following an acute myocardial infarction compared with patients 
without schizophrenia at 5 years
Unadjusted HR (95% CI)
Adjusted HR (95% CI)
Model 1 Model 2 Model 3
MACE 1.35 (1.23 to 1.47)* 2.44 (2.23 to 2.67)* 2.20 (1.79 to 2.72)* 2.05 (1.63 to 2.58)*
Mortality 1.44 (1.31 to 1.59)* 2.99 (2.72 to 3.29)* 2.53 (1.00 to 3.21)* 2.38 (1.84 to 3.09)*
Reinfarction 1.00 (0.82 to 1.24) 1.53 (1.25 to 1.89)* 1.41 (0.86 to 2.30) 1.29 (0.77 to 2.13)
Stroke 1.03 (0.80 to 1.34) 1.67 (1.29 to 2.17)* 1.72 (1.00 to 2.97) 1.72 (1.00 to 2.98)
Heart failure 1.25 (1.10 to 1.42)* 2.14 (1.88 to 2.42)* 1.49 (1.13 to 1.98)* 1.39 (1.04 to 1.86)*
Bleeding 1.09 (0.86 to 1.37) 1.55 (1.23 to 1.95)* 1.35 (0.85 to 2.14) 1.27 (0.79 to 2.05)
Model 1: adjusted for age and sex.
Model 2: adjusted for age, sex, smoking, comorbidities, previous CAG and previous PCI.
Model 3: adjusted for age, sex, smoking, comorbidities, previous CAG and previous PCI, discharge medications and treatment with CAG and 
PCI.
*p<0.005.
CAG, coronary angiography; MACE, major adverse cardiac outcome (all- cause mortality, rehospitalisation for AMI, hospitalisation for stroke 
or heart failure); PCI, percutaneous coronary intervention.
Figure 1 Kaplan- Meier survival curves showing the crude 
5- year estimates following AMI of (A) MACE (all- cause 
mortality, rehospitalisation for AMI, hospitalisation for stroke 
or heart failure), (B) all- cause mortality, (C) reinfarction, (D) 
stroke, (E) heart failure and (F) bleeding comparing patients 
with and without schizophrenia. AMI, acute myocardial 
infarction; MACE, major adverse cardiac events.
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underestimated prevalence. The 30- day blanking period of 
MI applied to avoid misclassification of reinfarctions could 
further contribute to this limitation, however, not blanking 
the period could have incorrectly inflated reinfarction rates.
CONCLUSION
Patients with schizophrenia experienced an AMI almost 
10 years earlier than patients without schizophrenia. They 
less often underwent invasive procedures and were less 
often treated with guideline recommended medications at 
discharge, and had more than doubled risk of MACE and all- 
cause mortality. Improved primary and secondary preventive 
measures, including adherence to guideline recommenda-
tions, are warranted and may improve outcome.
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